|Articles|January 10, 2023
Best Practices for 21 CFR Part 11 and GxP Validation for Electronic Records (Jan 2023)
Author(s)Egnyte
Drug development has dramatically changed over the past ten years. Specifically, when it comes to GxP compliance and validation. Many biopharma companies struggle to adopt new technologies because of the uncertainty of how to comply with FDA regulations. In this white paper, we will chronicle recent technological trends, specific challenges these trends pose for Quality & CSV teams, and best practices for tackling resulting compliance issues.
Related Content
Trending on Applied Clinical Trials Online
1
ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor
2
Patient Recruitment in Clinical Trials: Why the Industry's Longstanding Approach Is No Longer Fit for Purpose
3
ACT Brief: CRO Partnership in Program Recruitment, Psychedelic Trial Design Guidance, and Breast Cancer Pathway Inhibitor
4
FDA Finalizes Guidance on Clinical Trial Design for Psychedelic Drug Development
5